[Effect of the phytohepatoprotective agent maxar on the hepatic morphofunctional status in patients with chronic hepatitis].
The paper provides evidence for that as compared with the well-known drug carsil, the new Russian phytohepatoprotective agent maxar has a therapeutic efficiency in patients with mild and moderate chronic hepatitis (CH) of viral and alcoholic etiology. Maxar has been found to produce a more pronounced hepatoprotective effect, to a greater extent, in CH of alcoholic etiology.
Beloborodova
E I
EI
Gaĭsaev
R O
RO
Saratikov
A S
AS
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D005260:Female; D005419:Flavonoids / Q000627:therapeutic use*; D005500:Follow-Up Studies; D019694:Hepatitis B, Chronic / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D006519:Hepatitis, Alcoholic / Q000097:blood / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D015227:Lipid Peroxidation / Q000187:drug effects / Q000502:physiology*; D008099:Liver / Q000000981:diagnostic imaging / Q000187:drug effects* / Q000473:pathology; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D020011:Protective Agents / Q000627:therapeutic use*; D011877:Radionuclide Imaging; D012838:Silymarin / Q000627:therapeutic use; D016896:Treatment Outcome; D014463:Ultrasonography
D005419:Flavonoids; D020011:Protective Agents; D012838:Silymarin; D008315:Malondialdehyde; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin